Novo Holdings Crinetics Pharmaceuticals, Inc. Transaction History

Novo Holdings

$1.23 Billion
Q1 2024

A detailed history of Novo Holdings transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Novo Holdings holds 1,098,600 shares of CRNX stock, worth $49.2 Million. This represents 4.17% of its overall portfolio holdings.

Number of Shares

1,098,600

Previous 1,100,000 0.13%

Holding current value

$49.2 Million

Previous $39.1 Million 31.39%

% of portfolio

4.17%

Previous 3.29%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$34.76 - $46.81 $48,664 - $65,534	-1,400 Reduced 0.13%	1,098,600 $51.4 Million
Q1 2023 May 15, 2023	BUY	$15.31 - $21.1 $5.56 Million - $7.66 Million	362,943 Added 49.24%	1,100,000 $17.7 Million
Q4 2022 Feb 14, 2023	BUY	$15.49 - $19.05 $1.63 Million - $2.01 Million	105,430 Added 16.69%	737,057 $13.5 Million
Q2 2022 Aug 15, 2022	BUY	$16.49 - $27.64 $3.41 Million - $5.71 Million	206,730 Added 48.65%	631,627 $11.8 Million
Q1 2022 May 16, 2022	BUY	$17.15 - $28.31 $7.29 Million - $12 Million	424,897 New	424,897 $9.33 Million

Q2 2021 Aug 16, 2021	SELL	$15.9 - $21.15 $4.31 Million - $5.74 Million	-271,378 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$13.62 - $17.66 $775,318 - $1.01 Million	56,925 Added 26.54%	271,378 $4.25 Million
Q2 2020 Aug 14, 2020	BUY	$13.04 - $23.23 $652,000 - $1.16 Million	50,000 Added 30.4%	214,453 $3.76 Million
Q1 2020 May 15, 2020	BUY	$11.52 - $26.46 $339,194 - $779,088	29,444 Added 21.81%	164,453 $2.42 Million
Q4 2018 Feb 14, 2019	SELL	$22.4 - $35.39 $335,798 - $530,531	-14,991 Reduced 9.99%	135,009 $4.05 Million
Q3 2018 Nov 14, 2018	BUY	$22.66 - $36.8 $3.4 Million - $5.52 Million	150,000 New	150,000 $0

Others Institutions Holding CRNX

# of Institutions

220

Shares Held

75.8M

Call Options Held

631K

Put Options Held

749K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.41B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Novo Holdings, based on Form 13F filings with the SEC.

News

Stay updated on Novo Holdings with notifications on news.

Account